Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis-Reference-Cited by-同舟云学术

Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis

Published:2005-10 Issue:1-3 Volume:521 Page:156-163
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Ogawa Taketoshi,Sugidachi Atsuhiro,Tanaka Naoki,Fujimoto Koichi,Fukushige Jun-ichiro,Tani Yoshiro,Asai Fumitoshi

Publisher

Elsevier BV

Subject

Pharmacology

Reference33 articles.

1. Cerulein-induced pancreatitis in rats: increased lysosomal enzyme activity and autophagocytosis;Adler;Digestion,1985

2. Progression of alcoholic acute to chronic pancreatitis;Ammann;Gut,1994

3. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats;Cohen;Hypertension,1983

4. Mechanism of the hypotensive effect of ketanserin;Fozard;J. Cardiovasc. Pharmacol.,1982

5. Acute pancreatitis;Geokas;Ann. Intern. Med.,1972

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serotonin and Fibrosis;5-HT2B Receptors;2021

2. Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment;World Journal of Gastroenterology;2019-08-07

3. Serotonin in the gut: Blessing or a curse;Biochimie;2019-06

4. Tryptophan hydroxylase 1 and 5-HT7 receptor preferentially expressed in triple-negative breast cancer promote cancer progression through autocrine serotonin signaling;Molecular Cancer;2016-11-21

5. The results of the Tokyo Trial of Prevention of Post-ERCP Pancreatitis with Risperidone (Tokyo P3R): a multicenter, randomized, phase II, non-placebo-controlled trial;Journal of Gastroenterology;2012-10-24